Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma

Study Overview
=================
Brief Summary
-----------------
Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is constantly associated with progression of visual field loss. Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It is a known fact that glaucoma patients often require addition of a second antiglaucoma medications when disease progresses or tachyphylaxis occurs. It was reported that more than 50% of patients require 2 or more medications to achieve optimum IOP control. Nevertheless, compliance and adherence are often impaired with multiple-drug therapy. Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic regimen by reducing the number of medications used and the total number of doses administered.

Official Title
-----------------
Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma

Conditions
-----------------
Primary Open Angle Glaucoma

Intervention / Treatment
-----------------
* Drug: Latanoprost/Timolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and above Able to provide informed consent Diagnosed as having unilateral or bilateral, mild to moderate POAG The POAG treated with only two antiglaucoma Exclusion Criteria: Advanced POAG Patient with contraindication for topical use of a-blocker and prostaglandin analogue Patient with contraindication for systemic use of a-blocker Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol History of orbital or ocular trauma. History of cataract surgery less than 6 months. History of previous ocular surgery; e.g. vitreoretinal surgery, corneal transplantation or glaucoma surgery Any active eye infections or corneal ulceration. Patient with ocular surface disease Other ocular disease that might interfere with IOP measurements or result Precious eye i.e patient with only one good eye Contact lens is not allowed within 1 week before the start of study and during the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: A single-center, randomized open-labeled, prospective, crossover study.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: once daily group<br>Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate. For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day. | Drug: Latanoprost/Timolol<br>* Latanoprost/Timolol Fixed Combination<br>|
| Experimental: twice daily group<br>Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate. For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day. | Drug: Latanoprost/Timolol<br>* Latanoprost/Timolol Fixed Combination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: Intraocular pressure reduction | IOP reduction with LTFC given once and twice daily in POAG patients | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: Side effects | Side effects of LTFC given twice daily in POAG patients | 4 weeks |